Genomics is the study of your entire DNA – not just one or two genes. It helps us:

• Detect inherited conditions early
• Classify complex diseases like cancer more accurately
• Guide targeted therapies
• Predict treatment response and monitor residual disease
• Personalize care like never before

1. Benign Genomics
   1. Inherited cancer risk (e.g. BRCA1/2, Lynch syndrome)
   2. Thalassemia, sickle cell disease carrier screening
   3. Neurogenetics (epilepsy, ataxia, muscular dystrophy)
   4. Pediatric disorders (developmental delay, autism, syndromes)
   5. Cardiogenetics (arrhythmias, cardiomyopathies)
   6. Pharmacogenomics (drug metabolism and adverse reaction prediction)
   7. Nutrigenomics & Wellness
2. Malignant Genomics
   1. Solid Tumors: Breast, lung, colon, prostate, ovary, etc.
   2. Hematologic Malignancies: Leukemia, lymphoma, myeloma
   3. Liquid Biopsy & ctDNA for real-time cancer tracking
   4. CAR-T and transplant eligibility panels
   5. Minimal Residual Disease (MRD) by NGS
   6. CHIP and pre-leukemic state detection
   7. Fusion gene detection and novel mutation analysis

• India’s first real-time NGS platform (Ion Torrent Genexus) for same-day reports
• Multispecialty Genomic Tumor Boards
• AI Club-powered precision bioinformatics
• Home-grown expert team of molecular oncologists, geneticists, and bioinformaticians
• Integrated reporting aligned with global guidelines (AMP, CAP, ASCO, ACMG)
• Multi-language patient-centric reports for better understanding
• Genomic counseling for patients and families
• National registries and research leadership (e.g., AML, CHIP, CAR-T, lymphoma)
   

Fortis is proud to lead several national and institutional research initiatives:

• India’s largest AML Genomic Study
• ctDNA monitoring for DLBCL
• AI-based prediction models in transplant and cancer genomics
• Launch partner for India’s first Genomic Registry on CHIP and pre-malignant clones
   

We use cutting-edge genomic profiling to map the genetic mutations and alterations in cancer cells. By analyzing a patient’s tumor DNA and RNA, we can identify potential targets for therapy, predict how the tumor will respond to various treatments, and uncover new treatment options. This enables us to develop a personalized treatment plan tailored to the specific genetic landscape of the tumor.

Our Molecular Tumor Board brings together a team of multidisciplinary experts, including oncologists, geneticists, pathologists, and bioinformaticians, to discuss complex cancer cases. This collaborative approach ensures that patients benefit from the combined expertise of professionals who use genomic data to determine the most appropriate and personalized treatment plans.

Our team provides genetic counseling and tests for inherited mutations that could increase the risk of certain cancers. Through genetic testing and family history analysis, we offer patients valuable insights into their genetic predispositions, enabling them to make informed decisions regarding prevention, early detection, and proactive healthcare measures.

Understanding how an individual’s genetic makeup affects their response to medications is key to personalized cancer treatment. We utilize pharmacogenomic testing to guide clinicians in selecting the right drugs at the correct dosage for each patient, minimizing adverse effects and improving the overall effectiveness of the treatment.

The Fortis Institute is at the forefront of precision oncology, offering access to clinical trials that explore the latest in targeted therapies, immunotherapy, and gene-editing techniques. Our patients have the opportunity to participate in groundbreaking research, gaining access to innovative therapies that may not be available elsewhere.

1. Cancer
Genomic medicine is reshaping how we detect, assess, and treat cancer. Some people carry specific gene mutations that significantly raise their risk for certain cancers. For instance, individuals with a BRCA1 mutation can face up to an 80% lifetime chance of developing breast cancer. Similarly, those with familial adenomatous polyposis (FAP) are almost certain to develop colorectal cancer unless preventive measures are taken.

However, it's important to note that only around 5% to 10% of all cancers are directly linked to inherited genetic syndromes. In most families, cancer risk isn't elevated due to genetics alone. That’s why collecting a thorough family history remains crucial it helps determine whether genomic testing is needed or not.

Patients with lung cancer who have specifically ROS1 gene fusion often respond positively to targeted therapy with Crizotinib. In such cases, the disease is most effectively understood and managed based on its specific genetic alteration.

The number of individuals qualifying for genetic testing and enhanced cancer screening due to family history is steadily increasing, making genomics a central pillar of modern oncology & precision care. 

2. Rare, Inherited Diseases
There are over 7,000 known rare diseases, and the vast majority have a genetic origin. These conditions often manifest during childhood and can be challenging to diagnose using traditional methods.

Genomic testing has become a powerful tool in uncovering the causes of rare conditions. It helps not only in making a definitive diagnosis but also in guiding treatment plans and informing care strategies for family members who might be affected.

Advances in whole genome and exome sequencing are now giving answers to many individuals who previously remained undiagnosed, sometimes for years. As awareness and access to testing grow, more patients and families are benefiting from genomic insights every day.

3. Pharmacogenomics
Pharmacogenomics where genetics meets prescribing is transforming how medications are chosen for individual patients. Currently, it’s estimated that nearly 50% of prescribed drugs are either ineffective or cause unexpected side effects. This leads to avoidable health complications and places a substantial burden on healthcare systems.

By analyzing a person's genetic makeup, pharmacogenomics can predict how they’ll respond to certain medications whether the drug will work, whether it’s likely to cause harm, or if an alternative would be better.

For example, individuals with specific variants in the SLCO1B1 gene are at higher risk of developing muscle pain or myopathy when taking simvastatin, a common cholesterol-lowering drug. Having this information in advance helps clinicians make safer, more effective prescribing decisions.

As our understanding of gene-drug interactions deepens, pharmacogenomics is expected to play a growing role in everyday medical practice, especially in primary care.